Proposed model that integrates cholesterol bidirectional flux in the small intestine
Project/Area Number |
25504013
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Integrated Nutrition Science
|
Research Institution | Saitama Medical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
TAKENAKA Yasuhiro 埼玉医科大学, 医学部, 研究員 (20586789)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | コレステロール / 小腸 / 吸収 / コレステロール逆輸送 / エゼチミブ / Niemann-Pick C1-like 1 / コレステロール吸収制御 / 植物ステロール / NPC1L1 / ABCG5 / ABCG8 / 膜ホメオスタシス / 細胞内輸送 |
Outline of Final Research Achievements |
Ezetimibe inhibits Niemann-Pick C1-like 1 (NPC1L1), thereby reduces intestinal cholesterol absorption. This treatment also increases extrahepatic reverse cholesterol transport via an undefined mechanism. To explore this, we employed a trans-intestinal cholesterol efflux (TICE) assay and found an increase of TICE by 45%. To examine whether such increase in efflux occurs at the intestinal brush border membrane(BBM)-level, we performed luminal perfusion assays, similar to TICE but the jejunal wall was labelled with orally-given 3H-cholesterol, and determined elevated BBM-to-lumen cholesterol efflux by 3.5-fold with ezetimibe. Such increased efflux probably promotes circulation-to-lumen cholesterol transit eventually; thus increases TICE.
|
Report
(4 results)
Research Products
(5 results)